GH Research (GHRS) Set to Release Quarterly Earnings on Thursday

GH Research (NASDAQ:GHRS) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect GH Research to post earnings of ($0.3122) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

GH Research (NASDAQ:GHRS) last posted its earnings results on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. On average, analysts expect GH Research to post ($1.20) EPS for the current fiscal year and ($2.10) EPS for the next fiscal year.

GH Research Trading Down 1.7%

Shares of NASDAQ GHRS opened at $20.50 on Tuesday. GH Research has a 12-month low of $12.04 and a 12-month high of $31.44. The stock’s fifty day simple moving average is $23.90 and its two-hundred day simple moving average is $21.52. The stock has a market capitalization of $1.41 billion, a PE ratio of -20.50 and a beta of 1.32.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GHRS. HC Wainwright restated a “buy” rating on shares of GH Research in a research note on Monday, August 10th. Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research note on Thursday, October 15th. Cantor Fitzgerald boosted their target price on shares of GH Research from $35.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Wells Fargo & Company started coverage on shares of GH Research in a research report on Monday, July 27th. They set an “overweight” rating and a $44.00 price target for the company. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $45.00.

About GH Research

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration.